PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-30.79%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-31.28%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-21.00%
Negative EPS growth while Healthcare median is 4.76%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.22%
Negative diluted EPS growth while Healthcare median is 4.45%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
7.78%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
7.68%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Negative OCF growth while Healthcare median is 0.70%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-4.24%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
76.96%
OCF/share CAGR of 76.96% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
70.68%
3Y OCF/share growth of 70.68% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-11609.25%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.65%. Seth Klarman might see a fundamental problem if peers maintain growth.
81.05%
5Y net income/share CAGR > 1.5x Healthcare median of 8.46%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
70.82%
3Y net income/share CAGR > 1.5x Healthcare median of 4.59%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
881.79%
Equity/share CAGR of 881.79% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-26.92%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-79.64%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-41.29%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-11.75%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
20.45%
R&D growth of 20.45% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
69.30%
SG&A growth of 69.30% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.